Get to Know: Chase Schwalbach, Chief Product Officer, FidoCure
Tell us about your background
I grew up on the Ohio/Kentucky border, from a relatively modest background. My mom worked 3 jobs to support me and my 2 siblings, and I...
I grew up on the Ohio/Kentucky border, from a relatively modest background. My mom worked 3 jobs to support me and my 2 siblings, and I...
Resilience is defined as the capacity to recover quickly from difficulties and toughness-- there are both physical and psychological resilience. Both have been severely tested these last few years with the pandemic, the current war, national divisions, etc. and have really affected veterinarians in the world at large.
Veterinary medicine is changing. I remember one of my first days in veterinary school looking at the class pictures that were hung in the hallways. I remember seeing the first woman in one of these class photos and noting that she was still practicing.
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001 Morassa Mohseni, Ben Ho Park J Clin Invest. 2010;120(8):2655-2658. https://doi.org/10.1172/JCI44026.
This case study reviews the use of olacitinib to treat cutaneous epitheliotropic T-cell lymphoma (CETL).
The “Median Isn’t the Message” is an essay written by Stephen J. Gould in 1991 as part of his book Bully for Brontosaurus: Reflections in Natural History. The essay has been reprinted many times for many different audiences. In 2013 it was reprinted in the American Medical Association Journal of Ethics. I believe that Stephen J. Gould’s message is as relevant today as it was when he originally wrote it. I thought this essay so important and so well written, that it was required reading for every one of my residents over the past 20 years.
On Thursday June 10th at 3pm EST/12pm PST, we were delighted to welcome Dr. Liz Pluhar to our webinar series.
Dr. Pluhar is a full professor and small animal surgeon in the Department of Veterinary Clinical Sciences at the University of Minnesota and leads the Canine Brain Tumor Clinical Trials Program.
Melanocytic tumors are a relatively common group of neoplasms in dogs that originate from a pigment producing cell or melanocyte from the epidermis, dermis or hair follicles. Melanomas are the most common type of melanocytic tumor in the dog and affects approximately 19,000 dogs annually in the US, representing 7% of all malignant tumors in this species. Melanomas occurs in middle-aged to older dogs with mean age of 11.6 years, with no sex predisposition. Some breeds are more likely to develop melanoma in certain locations than others suggesting genetic factors are involved in melanoma development. The exposure to ultraviolet light is not a common etiology for most canine melanomas, as they occur predominantly in the mouth, at the nail bed, or on the skin which is typically covered by hair. This situation is similar to that for mucosal melanomas in people 1–5.
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. By Laura Marconato, et al(Cancers (Basel). 2020 May 18;12(5):1272. doi: 10.3390/cancers12051272).
What a week in our country. I can imagine that you may be feeling overwhelmed by the intensity of the news and pictures as I certainly am, as well as by the rapid pace of new information that keeps coming out.
DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2022 OHC, All rights reserved